沃森生物：持续推进新冠变异株mRNA疫苗研发

证券之星07-21

证券之星消息，沃森生物(300142)07月21日在投资者关系平台上答复投资者关心的问题。

投资者提问：你好董秘，目前新冠又有抬头的趋势，请问贵公司疫苗还研发吗？还是终止了？后续新股东会给公司哪些支持？目前公司有哪些马上要计划上市的新药？

沃森生物回复：尊敬的投资者，您好！公司严格按照国家药品注册程序的有关规定持续推进新型冠状病毒变异株mRNA疫苗（S蛋白嵌合体）、新型冠状病毒变异株mRNA疫苗（Omicron XBB.1.5）及其迭代疫苗新型冠状病毒变异株mRNA疫苗（Omicron JN.1）的研发和申报工作，关于公司在研产品的进展信息请以公司披露的公告为准。谢谢！

本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。

责任编辑：沈彬

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2653224894?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-07-21 15:03","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2653224894","market":"fut","top_or_hot":-1,"title":"沃森生物：持续推进新冠变异株mRNA疫苗研发","media":"证券之星","content":"<html><body><p>证券之星消息，<a href=\"https://laohu8.com/S/300142\">沃森生物</a>(300142)07月21日在投资者关系平台上答复投资者关心的问题。</p><p>投资者提问：你好董秘，目前新冠又有抬头的趋势，请问贵公司疫苗还研发吗？还是终止了？后续新股东会给公司哪些支持？目前公司有哪些马上要计划上市的新药？</p><p>沃森生物回复：尊敬的投资者，您好！公司严格按照国家药品注册程序的有关规定持续推进新型冠状病毒变异株mRNA疫苗（S蛋白嵌合体）、新型冠状病毒变异株mRNA疫苗（Omicron XBB.1.5）及其迭代疫苗新型冠状病毒变异株mRNA疫苗（Omicron JN.1）的研发和申报工作，关于公司在研产品的进展信息请以公司披露的公告为准。谢谢！</p><p>本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。</p><p>责任编辑：沈彬</p></body></html>","source":"stockstar","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>沃森生物：持续推进新冠变异株mRNA疫苗研发</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n沃森生物：持续推进新冠变异株mRNA疫苗研发\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-07-21 15:03 北京时间&nbsp;&nbsp;&nbsp;<a href=https://stock.stockstar.com/RB2026072100022824.shtml><strong>证券之星</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>证券之星消息，沃森生物(300142)07月21日在投资者关系平台上答复投资者关心的问题。投资者提问：你好董秘，目前新冠又有抬头的趋势，请问贵公司疫苗还研发吗？还是终止了？后续新股东会给公司哪些支持？目前公司有哪些马上要计划上市的新药？沃森生物回复：尊敬的投资者，您好！公司严格按照国家药品注册程序的有关规定持续推进新型冠状病毒变异株mRNA疫苗（S蛋白嵌合体）、新型冠状病毒变异株mRNA疫苗（...</p>\n\n<a href=\"https://stock.stockstar.com/RB2026072100022824.shtml\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"300142","symbol_name":"沃森生物","start_time":0,"source_url":"https://stock.stockstar.com/RB2026072100022824.shtml","article_id":"2653224894","we_media_id":"1082532455","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2653224894","pubTimestamp":1784617392,"columns":[],"sourceInfo":{"source_id":"stockstar","name":"证券之星"},"weMediaInfo":{"media_name":"证券之星","introduction":"证券之星始创于1996年，是国内领先的金融信息及综合服务平台。关注证券之星，即时获取有价值的财经资讯。","home_visible":1,"id":"1082532455","head_image":"https://community-static.tradeup.com/news/2e305640fc27210243042d09d3a7fa3f"},"summary":"证券之星消息，沃森生物07月21日在投资者关系平台上答复投资者关心的问题。公司严格按照国家药品注册程序的有关规定持续推进新型冠状病毒变异株mRNA疫苗、新型冠状病毒变异株mRNA疫苗及其迭代疫苗新型冠状病毒变异株mRNA疫苗的研发和申报工作，关于公司在研产品的进展信息请以公司披露的公告为准。","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"zh","relate_stocks":{"300142":"沃森生物","BK0077":"质押式回购","BK0046":"生物疫苗","BK0239":"医药制造","BK0070":"员工持股"},"translate_title":"Watson Bio: Continue to promote the research and development of mRNA vaccine for COVID-19 mutant strain","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"300142":1.5},"content_text":"证券之星消息，沃森生物(300142)07月21日在投资者关系平台上答复投资者关心的问题。投资者提问：你好董秘，目前新冠又有抬头的趋势，请问贵公司疫苗还研发吗？还是终止了？后续新股东会给公司哪些支持？目前公司有哪些马上要计划上市的新药？沃森生物回复：尊敬的投资者，您好！公司严格按照国家药品注册程序的有关规定持续推进新型冠状病毒变异株mRNA疫苗（S蛋白嵌合体）、新型冠状病毒变异株mRNA疫苗（Omicron XBB.1.5）及其迭代疫苗新型冠状病毒变异株mRNA疫苗（Omicron JN.1）的研发和申报工作，关于公司在研产品的进展信息请以公司披露的公告为准。谢谢！本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。责任编辑：沈彬","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2653224894","isCrawlerRequest":true}